Takeda posts 14% first-qtr revenues growth

31 July 2024

Japan’s largest drugmaker Takeda (TYO: 4502) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), showing that net profit increased 6.5% from a year earlier to 95.25 billion yen ($623.4 million). That exceeded the estimate of 53.24 billion yen in a poll of analysts by data provider Quick.

First-quarter revenue rose 14% to 1.208 trillion yen, thanks to sales growth of several key products and a weaker yen. Sales of ulcerative colitis drug Entyvio (vedolizumab) climbed 22% to 234.4 billion yen and sales of plasma-derived products increased 30% to 271.4 billion yen.

Meanwhile, sales of Vyvanse (lisdexamfetamine dimesylate) dropped 6.9% to 114.6 billion yen after Takeda lost US market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK